Avita Medical touts ReCell skin graft study data

This study suggests that its use [on] skin graft donor [sites] should promote healing and improve long-term aesthetic results,” trial investigators wrote. In evaluations of the donor sites, both patients and independent observers reported that the sites treated with autologous skin cell suspension “displayed better physical attributes” and patients were reportedly more satisfied with the healing quality. “We are excited about these results, as together, the data show that ReCell can be deployed both to reduce patient trauma, and to help patients heal faster. Our pivotal trial in the US, announced last month, showed how ReCell allowed doctors to successfully treat burns using about 30% less donor skin. Now, in China, surgeons have shown that the donor site itself can heal some 30% faster when treated with Regenerative Epithelial Suspension made using the ReCell device. Demonstration of clinical benefit for treatment of burn injuries and treatment of donor sites further substantiates the key, versatile role for ReCell in burn care,” CEO Mike Perry said in a press release. In May, Avita Medical saw shares rise over 5% after announcing that the pivotal clinical trial of its regenerative ReCell device for treating severe burns met both co-primary endpoints. The post Avita Medical touts ReCell skin graft study data appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Regenerative Medicine Avita Medical Ltd. Source Type: news